| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $11,999,922 | 2 | 7 |
Sells | $19,442,069 | 26 | 93 |
| AKKARAJU SRINIVAS | director | 2 | $12M | 0 | $0 | $12M |
| Gilman Michael | director | 0 | $0 | 1 | $137,058 | $-137,058 |
| Burow Kristina | director | 0 | $0 | 1 | $164,064 | $-164,064 |
| Reed Joshua | director | 0 | $0 | 1 | $164,067 | $-164,067 |
| FLIER JEFFREY S. | director | 0 | $0 | 1 | $164,490 | $-164,490 |
| Peng Katie | director | 0 | $0 | 2 | $337,756 | $-337,756 |
| Marantz Jing L. | CHIEF MEDICAL OFFICER | 0 | $0 | 2 | $451,299 | $-451,299 |
| Parlavecchio Caryn | CHRO | 0 | $0 | 2 | $713,935 | $-713,935 |
| Ho Junlin | GENERAL COUNSEL | 0 | $0 | 2 | $802,273 | $-802,273 |
| Woods Keith | Chief Operating Officer | 0 | $0 | 2 | $1.22M | $-1.22M |
| Sinha Vikas | Chief Financial Officer | 0 | $0 | 2 | $1.23M | $-1.23M |
| Vaishnaw Akshay | President of R&D | 0 | $0 | 2 | $1.48M | $-1.48M |
| Hallal David | Chief Executive Officer | 0 | $0 | 2 | $3.97M | $-3.97M |
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 6 | $8.6M | $-8.6M |
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established …
Over the last 12 months, insiders at Scholar Rock Holding Corporation have bought $12M and sold $19.44M worth of Scholar Rock Holding Corporation stock.
On average, over the past 5 years, insiders at Scholar Rock Holding Corporation have bought $19.89M and sold $33.91M worth of stock each year.
Highest buying activity among insiders over the last 12 months: AKKARAJU SRINIVAS (director) — $12M.
The last purchase of 146,970 shares for transaction amount of $6.11M was made by AKKARAJU SRINIVAS (director) on 2026‑10‑26.
| 2026-10-26 | AKKARAJU SRINIVAS | director | 146,970 0.1122% | $41.59 | $6.11M | +4.47% | ||
| 2026-10-23 | AKKARAJU SRINIVAS | director | 142,500 0.1086% | $41.32 | $5.89M | +4.24% | ||
| 2026-07-01 | Sale | Burow Kristina | director | 3,053 0.0026% | $53.74 | $164,064 | -6.36% | |
| 2026-07-01 | Sale | Gilman Michael | director | 2,544 0.0022% | $53.88 | $137,058 | -6.36% | |
| 2026-07-01 | Sale | Peng Katie | director | 5,446 0.0046% | $53.88 | $293,405 | -6.36% | |
| 2026-07-01 | Sale | FLIER JEFFREY S. | director | 3,053 0.0026% | $53.88 | $164,490 | -6.36% | |
| 2026-07-01 | Sale | Reed Joshua | director | 3,053 0.0026% | $53.74 | $164,067 | -6.36% | |
| 2026-04-16 | Sale | Hallal David | Chief Executive Officer | 30,615 0.0264% | $49.57 | $1.52M | -2.78% | |
| 2026-04-16 | Sale | Vaishnaw Akshay | President of R&D | 12,246 0.0106% | $49.57 | $607,089 | -2.78% | |
| 2026-04-16 | Sale | Woods Keith | Chief Operating Officer | 10,220 0.0088% | $49.57 | $506,651 | -2.78% | |
| 2026-04-16 | Sale | Sinha Vikas | Chief Financial Officer | 10,410 0.009% | $49.57 | $516,071 | -2.78% | |
| 2026-02-23 | Sale | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 8,484 0.0083% | $47.07 | $399,351 | +2.41% | |
| 2026-02-17 | Sale | Ho Junlin | GENERAL COUNSEL | 9,580 0.0094% | $46.53 | $445,740 | +3.44% | |
| 2026-02-17 | Sale | Parlavecchio Caryn | CHRO | 9,035 0.0089% | $46.53 | $420,382 | +3.44% | |
| 2026-02-17 | Sale | Marantz Jing L. | CHIEF MEDICAL OFFICER | 4,157 0.0041% | $46.53 | $193,418 | +3.44% | |
| 2026-02-17 | Sale | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 7,989 0.0078% | $46.53 | $371,714 | +3.44% | |
| 2026-01-22 | Sale | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 14,898 0.0143% | $46.71 | $695,938 | -0.13% | |
| 2026-01-16 | Sale | Ho Junlin | GENERAL COUNSEL | 8,016 0.0078% | $44.48 | $356,533 | +6.04% | |
| 2026-01-16 | Sale | Parlavecchio Caryn | CHRO | 6,600 0.0064% | $44.48 | $293,553 | +6.04% | |
| 2026-01-16 | Sale | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 8,406 0.0082% | $44.48 | $373,880 | +6.04% |
| AKKARAJU SRINIVAS | director | 6380517 5.2392% | $280.62M | 6 | 1 | +19.94% |
| Invus Public Equities, L.P. | 10 percent owner | 9250005 7.5954% | $406.82M | 4 | 3 | +12.47% |
| Invus Public Equities Advisors, LLC | director | 8850005 7.2669% | $389.22M | 2 | 0 | +3.94% |
| Samsara BioCapital GP, LLC | 10 percent owner | 6788609 5.5743% | $298.56M | 1 | 0 | |
| SPRINGER TIMOTHY A | 3273519 2.6879% | $143.97M | 1 | 0 | +17.37% | |
| Nashat Amir | 2676311 2.1976% | $117.7M | 1 | 0 | +17.37% | |
| Polaris Venture Management Co. VI, L.L.C. | 10 percent owner | 2676311 2.1976% | $117.7M | 1 | 0 | +17.37% |
| Artal International S.C.A. | 10 percent owner | 450000 0.3695% | $19.79M | 1 | 0 | +17.37% |
$67,892,722 | 138 | 28.28% | $6.25B | |
$224,662,742 | 52 | 32.03% | $5.65B | |
$613,304,943 | 46 | 11.85% | $6.22B | |
$11,583,737 | 45 | 49.75% | $4.66B | |
$477,065,869 | 34 | 82.05% | $6B |
| Increased Positions | 178 | +73.55% | 23M | +19.38% |
| Decreased Positions | 104 | -42.98% | 16M | -13.48% |
| New Positions | 79 | New | 3M | New |
| Sold Out Positions | 36 | Sold Out | 7M | Sold Out |
| Total Postitions | 316 | +30.58% | 124M | +5.91% |
| Fmr Llc | $599,717.00 | 13.74% | 14.01M | +177,203 | +1.28% | 2025-09-30 |
| Siren, L.L.C. | $395,900.00 | 9.07% | 9.25M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $294,595.00 | 6.75% | 6.88M | -2M | -21.44% | 2025-09-30 |
| Blackrock, Inc. | $289,336.00 | 6.63% | 6.76M | +64,307 | +0.96% | 2025-09-30 |
| Samsara Biocapital, Llc | $240,232.00 | 5.5% | 5.61M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $210,359.00 | 4.82% | 4.91M | +53,333 | +1.1% | 2025-09-30 |
| Wellington Management Group Llp | $194,564.00 | 4.46% | 4.55M | +3M | +124.5% | 2025-09-30 |
| Redmile Group, Llc | $167,111.00 | 3.83% | 3.9M | -24,583 | -0.63% | 2025-09-30 |
| State Street Corp | $161,061.00 | 3.69% | 3.76M | +688,807 | +22.41% | 2025-09-30 |
| Bellevue Group Ag | $138,866.00 | 3.18% | 3.24M | +297,242 | +10.09% | 2025-09-30 |